Latest Ai Platforms News

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Straker Ltd’s H1 FY26 results reveal a strategic shift from legacy translation services to AI-driven specialised language models, anchored by a $28 million partnership with IBM. Despite a 15% revenue decline, the company maintains positive adjusted EBITDA and a strong balance sheet.

Straker Ltd reports a solid first half of FY26 with positive EBITDA and a renewed IBM partnership, despite a 15% revenue decline amid challenging market conditions.

Icetana reveals its FY26 strategy focused on transforming Security Operations Centers with predictive, explainable, and autonomous AI, aiming to enhance threat detection and operational efficiency.

Decidr AI Industries has announced a strategic acquisition of Delaware-based Sugarwork Inc., marking its official entry into the US market and enhancing its Agentic AI platform with advanced knowledge transfer capabilities.

Nexion Group has finalized the sale of its Nexion Networks and Blue Sky Telecom subsidiaries, pivoting its focus towards AI-driven business intelligence through Fuse Forward.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Activeport Group Ltd has launched a new AI model routing platform that leverages its GPU orchestration expertise to deliver secure, sovereign AI hosting with hybrid cloud compatibility.

Artrya Limited has expanded its SAPPHIRE clinical study with Ascension, one of the largest US non-profit health systems, joining as the fourth major participant. This move strengthens the study’s reach and advances the evaluation of Artrya’s AI-powered Salix platform for coronary artery disease detection.

Xero Limited reports a robust 20% revenue increase in H1 FY26, driven by strong subscriber growth and the strategic Melio acquisition. The company’s innovative AI platform and improved profitability underscore its confident path toward accelerated US market expansion.

BrainChip Holdings Ltd has launched a fully underwritten $35 million placement alongside a $2 million share purchase plan to fund the commercialization of its Akida 2.0 technology and new TENNs product development. The capital raise underscores the company’s commitment to expanding its footprint in the rapidly growing edge AI market.